Pfizer/Bristol drug cuts recurrence of blood clots – study

(Reuters) – A new blood clot preventer from Pfizer Inc and Bristol-Myers Squibb Co reduced the risk of recurrence of clots in veins and lungs and death by 80 percent with no increase in major bleeding in a study testing extended use of the drug.

In the year-long trial of 2,486 patients who had been previously treated for the condition known as venous thromboembolism (VTE) the drug, apixaban, met the combined primary goal by significantly reducing the recurrence of blood clots and death from any cause compared with a placebo, according to data presented at the American Society of Hematology (ASH) meeting in Atlanta, Georgia.

The rate of recurrence or death was 11.6 percent in the placebo group compared with 3.8 percent for those who got 2.5 milligrams of apixaban and 4.2 percent for the 5 mg dose of the drug. The results were also published in the New England Journal of Medicine.

The incidence of major bleeding, always a concern with blood thinners, was extremely low in all three arms of the trial, researchers said – 0.5 percent for placebo, 0.2 percent for the low dose of apixaban and 0.1 percent for the higher dose.

“Usually when you have an effective antithrombotic you have to pay a price in terms of bleeding. This was not the case in this study,” Dr. Giancarlo Agnelli, the study’s principal investigator, said in a telephone interview.

“There was no evidence at all of increased major bleeding and this is extremely important because you are comparing an active drug with placebo,” he said.

There was a slightly higher rate of clinically relevant nonmajor bleeding, such as nose bleeds that required medical attention, observed in patients taking the higher dose of apixaban at 4.2 percent compared with the low dose and placebo, researchers said.

Apixaban belongs to a new class of blood thinners that aim to replace decades old and difficult to use warfarin. The drug, which will be sold under the brand name Eliquis, is widely considered to be one of the most important new medicines for Pfizer and Bristol-Myers, both of which saw their top selling products lose patent protection in the past year.

AWAITING U.S. APPROVAL

It is approved in Europe and awaiting a U.S. approval decision for preventing blood clots and strokes in patients with atrial fibrillation – a type of irregular heart beat – and is also being tested against warfarin as a primary treatment for VTE with data expected next year.

A rival drug from Bayer and Johnson & Johnson called Xarelto is already approved for both conditions, but based on clinical data analysts have said they believe Eliquis is the best class.

An approval for extended use in VTE patients, during which they would take the drug for at least a year after initial treatment, could significantly boost future sales.

“The evidence is for one year. The next step would be to see whether this clinical benefit is extended after one year,” Agnelli said.

VTE consists of deep vein thrombosis, typically blood clots in the legs, and pulmonary embolism, which are dangerous clots in the lungs. Clots that begin in the extremities can travel to the heart and lungs and can be fatal. VTE is typically treated with warfarin for three to six months.

After that, “there is quite a remarkable level of uncertainty about whether to extend or not,” explained Agnelli, professor of internal medicine at the University of Perugia in Italy, who presented the data at the ASH meeting.

“Extended treatment might be clinically relevant because the recurrence rate after stopping treatment can be 10 percent in the first year,” Agnelli said. “Reducing the recurrence of VTE means reduced hospitalization costs and in some cases fewer fatal events.”

Physicians have been looking for alternatives to warfarin, which must be closely monitored to keep levels therapeutic but not toxic. The new drugs do not require monitoring or the dietary and lifestyle changes necessary with warfarin. But they still face an uphill battle as warfarin is far less expensive, and doctors have a comfort level using a drug that has been around for more than half a century despite the challenges.

Patients in the study had received treatment with warfarin for six to 12 months before starting the one-year extension trial that aimed to show further treatment could reduce recurrence rates and to see if the lower dose of apixaban was a viable option.

“It is quite clear that the lower dose is as effective as the higher. For the first time we showed that by reducing the dose of an antithrombotic agent in this clinical setting we can have the same efficacy with no major bleeding,” Agnelli said.

“This is actually something that could change clinical practice,” he added.

(Reporting by Bill Berkrot; Editing by Jilian Mincer, Berard Orr)

Health News Headlines – Yahoo! News

Read More..

Investors offer about $38.8 billion euros in Greek debt buyback: source

ATHENS (Reuters) – Greece is set to purchase back about half of its debt owned by private investors, broadly succeeding in a bond buyback that is key to the country’s international bailout, a Greek government official said on Saturday.

Greek and foreign bondholders offered the targeted 30 billion euros ($ 38.8 billion) in the deal, which is central to efforts by Greece’s euro zone and International Monetary Fund lenders to cut its debt to manageable levels.

“The buyback went well in broad terms. The amount offered by investors was within the range expected, about 30 billion euros,” the official told Reuters on condition of anonymity. He did not provide more details.

No formal announcement is expected before Monday, another official told Reuters.

The buyback accounts for about half of a broader, 40-billion euro EU/IMF debt relief package for Athens agreed in November. The package broadly doubles the average maturity of its rescue loans to almost 30 years and cuts its interest rates by one percentage point to a level far below 1 percent.

Under its terms, Athens will spend up to 10 billion euros of borrowed money to buy back bonds with a nominal value of about 30 billion euros. This is nearly half the 63 billion euros of Greek debt held by private investors eligible for the plan.

Since the bonds are to be bought far below their nominal value, the country’s net debt burden would fall by about 20 billion euros.

A successful buyback will ensure that the IMF, which contributes about a third of Greece’s bailout loans, will stay on board of the rescue. It would also unlock the payment of 34.4 billion euros of aid later this month.

Athens badly needs that money to refloat its ailing economy by replenishing the capital of its cash-strapped banks and settle arrears with government suppliers.

The EU and the IMF have been withholding rescue payments to Greece for six months because it had fallen short of promises to shore up its finances, privatize and make its economy more competitive.

Athens has received 148.6 billion euros in EU/IMF funds since May 2010. It stands to get almost 90 billion euros more by the end of 2014.

But the rescue comes at a heavy price. Austerity measures taken in exchange for aid have plunged the country into economic depression. Unemployment hit a record 26 percent in September, the highest in the euro zone.

The economy is going through its fifth consecutive year of recession and is expected to have shrunk by 24 percent when recovery begins in 2014.

GREEK BANKS ON BOARD

The buyback was expected to go well after Greek banks, which hold about 17 billion euros of bonds, announced shortly before a Friday deadline they would take part. Two Cypriot lenders also said they would offer their bonds.

Foreign investors have offered between 15 and 16 billion euros worth of bonds, Greek newspapers reported on Saturday, citing initial estimates without saying how they got them.

Athens’ hopes of drawing enough investors to the scheme grew after it announced better-than-expected terms on Monday, with price ranges at a premium over market prices.

The price range varied from a minimum of 30.2 to 38.1 percent and a maximum of 32.2 to 40.1 percent of the principal amount, depending on the maturities of the 20 series of outstanding bonds.

Hedge funds, which bought the debt at rock-bottom prices when it was feared the country would exit the euro, are estimated to hold a large part of Greek debt and the offer was seen as good enough to make them a nice profit.

“Athens put forth a reasonable if not generous offer for hedge funds to participate,” Sassan Ghahramani, CEO at New York-based Macro Advisers, a hedge fund consultancy, said on Friday.

“I expect there will be strong participation from hedge funds, tendering a substantial portion of their Greek bond holdings,” he said.

The government also enticed Greek bankers by offering to protect them from possible shareholder lawsuits stemming from the buyback.

Greek bankers had been reluctant to take part, in the fear they would book losses on top of the ones they incurred earlier this year when Athens enforced a debt cut on its bondholders.

But the lenders were nevertheless expected to participate because they depend on the bailout funds that Athens stands to receive if its bailout continues smoothly.

($ 1 = 0.7735 euros)

(Writing by Harry Papachristou; editing by James Jukwey)

Business News Headlines – Yahoo! News

Read More..

‘Post-PC’ is more than just marketing buzz for Apple CEO Tim Cook

Apple (AAPL) is no stranger to ditching technologies when it deems them to no longer be useful. The company dropped the floppy disk for a CD-ROM drive on the first iMac and most recently has shifted to building MacBooks and iMacs without any physical disc drives. In his first televised interview on NBC’s Rockcenter with Brian Williams, Apple CEO Tim Cook revealed that he has “ditched physical keyboards” now that he spends 80% of his time using his iPad “authoring email” and “working on things.” Cook says he’s gotten quite good at typing on the screen and advises people to trust auto-correction as it’s “quite good” — though it’s a feature we still blast iOS for some five years after the first iPhone launched. But what does it mean when the boss of the country’s most valuable company and the most revered technology company in the world doesn’t even use physical keyboards anymore? Perhaps the “post-PC” era will become mainstream sooner than we thought.

For years, Apple has touted the idea that we’re entering the “post-PC” era – a period when touchscreen-equipped smartphones and tablets will eclipse desktops, notebooks and complex operating systems as they slowly fade away into a niche reserved for professionals.

While there will still be a need for notebooks, Windows PCs and Macs, the increasing numbers of smartphones and tablets sold and continued decline of worldwide PC sales support Apple’s claim that mobile is where the next tech battleground is, even if Microsoft (MSFT) thinks otherwise.

The term “dogfooding” is often thrown around between tech blogs and Cook is doing exactly that — using his “own product to demonstrate the quality and capabilities of the product.”

As Steve Jobs once said, Apple only builds products its own engineers and designers would use themselves.

Cook’s not saying, “iPads are great” for some people and some tasks. The fact that Cook uses his iPad for 80% of his work and an iPhone all the time suggests he and Apple are serious about this post-PC era. Apple wants iPads and iPhones to be great for all of your computing needs.

Apple is serious enough about it that the big boss has shifted his habits from old-school typing on actual keyboards to using virtual keyboards. And for all we know, Cook could be using even more natural human interfaces such as more voice recognition (ex: Siri in iOS and built-in dictation in OS X Mountain Lion).

Will physical keyboards go the way of the dodo in the next handful of years? It’s doubtful, but don’t be surprised if you see fewer and fewer offices with QWERTY keyboards attached to PCs and more desks and execs just carrying tablets and a smartphone on the side.

Get more from BGR.com: Follow us on Twitter, Facebook

Gadgets News Headlines – Yahoo! News

Read More..

UK’s Kate and William “saddened” by nurse’s death

LONDON (Reuters) – Britain’s Prince William and his wife Kate said on Friday they were “deeply saddened” by the death of a nurse who fell victim to a prank call from an Australian radio station seeking details of the duchess’s condition while she was in hospital for morning sickness.

The King Edward VII hospital earlier confirmed the death of the nurse, Jacinda Saldanha.

“Their Royal Highnesses were looked after so wonderfully well at all times by everybody at King Edward VII Hospital, and their thoughts and prayers are with Jacintha Saldanha‘s family, friends and colleagues at this very sad time,” said a statement from William’s office.

(Reporting by Tim Castle; editing by Stephen Addison)

Celebrity News Headlines – Yahoo! News

Read More..

GlaxoSmithKline in deal with MD Anderson on cancer drugs

(Reuters) – GlaxoSmithKline signed a collaboration agreement with the MD Anderson Cancer Center in Houston to develop new drugs that promote a patient’s immune system to attack cancer based on discoveries by Anderson researchers.

Anderson, one of the world’s premier cancer research and treatment centers, announced the agreement on Friday. Under terms of the deal, it will receive an undisclosed upfront payment and research funding from Glaxo and could earn $ 335 million plus royalties if the collaboration leads to approved medicines.

The British drugmaker will get exclusive worldwide rights to develop and sell antibodies that activate OX40, a protein on the surface of T cells – a type of white blood cell that is an important component of the body’s immune system. The antibodies were discovered by Dr. Yong-Jun Liu and colleagues when he was professor and chair of MD Anderson’s Department of Immunology.

“This agreement is … a testament to the vision shared by GSK and MD Anderson that successful clinical development of oncology drugs requires seamless integration of drug development expertise and deep biological knowledge,” Dr Giulio Draetta, director of Anderson’s Institute for Applied Cancer Science, said in a statement.

So-called immunotherapies, which help the body’s immune system to more efficiently attack cancer, are seen as an important new frontier is the fight against the disease in its many forms. Several companies are developing promising cancer immunotherapies.

Any drugs that come out of the Glaxo-Anderson collaboration would be several years away as more preclinical testing is needed before the OX40 approach will be tested in human subjects, MD Anderson said.

(Reporting by Bill Berkrot; Editing by Nick Zieminski)

Medications/Drugs News Headlines – Yahoo! News

Read More..

US jobless rate at four-year low

7 December 2012 Last updated at 11:29 ET

The US added 146,000 jobs in November, official data shows, as the economy seemingly shrugged off storm Sandy.

The unexpectedly strong performance brought the unemployment rate down to a four-year low of 7.7% of the workforce.

The jobs figure was well above most analysts’ expectations and continued a recent surge that began in July.

Weekly benefits data registered a sharp but short-lived jump in the number claiming unemployment benefits in the states ravaged by the storm last month.

“Our analysis leads us to conclude that Hurricane Sandy did not substantively impact the national employment and unemployment estimates for November,” said John Galvin, acting commissioner at the Bureau of Labour Statistics (BLS), which produced the jobs report.

The jobs survey data for the individual states – which can be used by analysts to determine what effect, if any, the storm had – will not be released until 21 December.

Wobbly confidence

Stock markets gave the figures a cautiously positive response, with both the Dow Jones and S&P 500 indexes rising 0.3% at the start of trading on Wall Street.

European shares, which had been down for the day following a cut in the Bundesbank’s growth forecast for Germany, jumped about 0.5% on the news.

The US Federal Reserve is due to meet next week to decide whether to expand the central bank’s policy of buying up debt from the markets in order to stimulate the recovery.

Continue reading the main story

US government bonds fell slightly in value following the data release, suggesting that markets have lowered the expectations for further intervention by the Fed in light of the strong jobs growth figure.

However, the Fed’s Open Market Committee will also have to weigh the latest consumer confidence survey, also released on Friday, which saw a sharp fall in sentiment in early December.

The University of Michigan’s consumer sentiment index fell to 74.5 from 82.7 the previous month, reaching a level normally associated with recession, although it was still well above the 55 registered at the depth of the 2008 downturn.

The drop in confidence among ordinary Americans may reflect the impasse in Congress in negotiations to avert the “fiscal cliff” of automatic spending cuts and tax rises that kicks in on 1 January.

Consumer sentiment briefly plummeted in 2011 when the US lost its top triple-A after a similar stand-off over the raising of the legal cap on the US federal government’s ability to borrow.

Mixed message

Although the latest jobs report beat expectations, this was in large part because expectations remain very low.

The number of jobs being added by the US economy since the recession ended has been far weaker than during previous economic recoveries, and has scarcely been enough to keep up with the natural growth in the US population.

The total number of people in employment has been stuck at about 58% of the US population since 2009, well down from the 63% level that characterised the boom years of the past decade, as many Americans have retired or given up seeking work.

Moreover, the relatively good news for November was offset by the BLS’s decision to downwardly revise the jobs figures for the preceding two months by a cumulative total of 49,000.

The October figure – which was originally reported just before the elections as 171,000, prompting some Republican supporters to suggest that the numbers had been manipulated – has been cut in the latest estimate to 138,000.

However, the reduction in the October figure was actually entirely due to public sector jobs cuts – mainly at the state and local government level – being 35,000 higher than originally estimated.

“While more work remains to be done, today’s employment report provides further evidence that the US economy is continuing to heal from the wounds inflicted by the worst downturn since the Great Depression,” said Alan Krueger, chairman of the White House Council of Economic Advisors.

Dropping out

The unemployment rate – which fell to 7.7% in November, down from 7.9% in October – has fallen in fits and starts over the past three years, since peaking at 10% in late 2008, but still remains some way short of the 5% level that has accompanied periods of healthy growth in the past two decades.

The total number of unemployed people remained largely unchanged in the latest month at about 12 million, as did the number of people out of work for over half a year, at 4.8 million. The number of people taking part-time jobs because they cannot find full-time work also remained unchanged at 8.2 million.

Statistics suggest that much of the decline in the unemployment rate since 2008 has been due to people dropping out of the workforce, either due to retirement or because they have given up seeking work.

The unemployment figure only includes those actively seeking a job, and once people stop doing so they drop out of the statistics.

The retail sector continued to lead the way in job creation, with professional services and IT also providing large contributions, while the construction sector, food manufacturing and chemicals saw sizeable job losses.

BBC News – Business

Read More..

Toronto mayor to stay in power pending appeal of ouster

TORONTO (Reuters) – Toronto Mayor Rob Ford can stay in power pending an appeal of a conflict of interest ruling that ordered him out of his job as leader of Canada’s biggest city, a court ruled on Wednesday.

Madam Justice Gladys Pardu of the Ontario Divisional Court suspended a previous court ruling that said Ford should be ousted. Ford’s appeal of that ruling is set to be heard on January 7, but a decision on the appeal could take months.

Justice Pardu stressed that if she had not suspended the ruling, Ford would have been out of office by next week. “Significant uncertainty would result and needless expenses may be incurred if a by-election is called,” she said.

If Ford wins his appeal, he will get to keep his job until his term ends at the end of 2014. If he loses, the city council will either appoint a successor or call a special election, in which Ford is likely to run again.

“I can’t wait for the appeal, and I’m going to carry on doing what the people elected me to do,” Ford told reporters at City Hall following the decision.

Ford, a larger-than-life character who took power on a promise to “stop the gravy train” at City Hall, has argued that he did nothing wrong when he voted to overturn an order that he repay money that lobbyists had given to a charity he runs.

Superior Court Justice Charles Hackland disagreed, ruling last week that Ford acted with “willful blindness” in the case, and must leave office by December 10.

Ford was elected mayor in a landslide in 2010, but slashing costs without cutting services proved harder than he expected, and his popularity has fallen steeply.

He grabbed unwelcome headlines for reading while driving on a city expressway, for calling the police when a comedian tried to film part of a popular TV show outside his home, and after reports that city resources were used to help administer the high-school football team he coaches.

The conflict-of-interest drama began in 2010 when Ford, then a city councillor, used government letterhead to solicit donations for the football charity created in his name for underprivileged children.

Toronto’s integrity commissioner ordered Ford to repay the C$ 3,150 ($ 3,173) the charity received from lobbyists and companies that do business with the city.

Ford refused to repay the money, and in February 2012 he took part in a city council debate on the matter and then voted to remove the sanctions against him – despite being warned by the council speaker that voting would break the rules.

He pleaded not guilty in September, stating that he believed there was no conflict of interest as there was no financial benefit for the city. The judge dismissed that argument.

In a rare apology after last week’s court ruling, he said the matter began “because I love to help kids play football”.

Ford faces separate charges in a C$ 6 million libel case about remarks he made about corruption at City Hall, and is being audited for his campaign finances. The penalty in the audit case could also include removal from office.

(Reporting by Claire Sibonney; Editing by Janet Guttsman, Russ Blinch, Nick Zieminski; and Peter Galloway)

Canada News Headlines – Yahoo! News

Read More..

mtvU honors Frank Ocean, wounded Pakistani teen

NEW YORK (AP) — The mtvU network is honoring a rap superstar who detailed his love for another man and a Pakistani girl shot for her education advocacy as its Man and Woman of the Year.

Frank Ocean, who earned six Grammy nominations Wednesday, published a letter online about his first love, a man, just as his “channel ORANGE” disc was being released. MtvU on Thursday called it “an incredibly brave move for an artist on the verge of superstardom.”

Fifteen-year-old Malala Yousufzai (mah-LAH’-lah YOO’-suf-ZAY’) blogged about her support of education for girls in Pakistan. For that, Taliban militants stormed her school bus and shot her in the head and neck, but she survived.

The mtvU network is geared toward college students and is seen on more than 750 campuses.

Entertainment News Headlines – Yahoo! News

Read More..

Vitamin D, calcium disappoint in dementia study

NEW YORK (Reuters Health) – Vitamin D and calcium supplements taken together in low doses offered no protection against dementia in a large U.S. study of older women, but scientists are still holding out hope for vitamin D alone.

Past research has suggested that vitamin D might protect against memory loss and overall functional decline in the aging brain. But more than 2,000 women in the new study who took 400 international units of vitamin D and 1,000 mg of calcium daily for an average of eight years developed cognitive impairments at the same rates as a comparison group on placebo pills.

During the many years that study was ongoing, however, experts gained a better understanding of how calcium and vitamin D might have conflicting effects, so the combination of the two might explain the disappointing results, the study’s authors say.

“I think the definitive study will just look at the effects of vitamin D,” said lead author Dr. Rebecca Rossom, from HealthPartners Institute for Education and Research, a nonprofit arm of a health maintenance organization (HMO) based in Minneapolis.

But this study is important because it “gets closer to how women take vitamin D now,” as a way build bone density, Rossom added.

Her team’s report, which is published in the Journal of the American Geriatrics Society, is also the first to use the rigorous approach known as a randomized, double-blind trial with a placebo group to look at the possible effects of vitamin D and calcium on cognitive decline.

Rossom and her colleagues analyzed data on 4,100 women who were simultaneously enrolled in two trials, including the Women’s Health Initiative (WHI) Calcium and Vitamin D trial that ended in 2005, and a WHI memory study.

All of the women, who averaged 71 years old at the outset of the studies, were also free of cognitive problems to start.

Half of the women were assigned to take the supplements and the rest were given identical looking dummy pills.

Ultimately, about 100 women, or five percent, in each group developed mild cognitive impairment – a term that can include everything from memory trouble to the serious dementia found in Alzheimer’s disease.

The researchers note that since the study ended, guidelines on vitamin and mineral intakes have changed. Currently the U.S. Institute of Medicine suggests getting 600 IUs per day of vitamin D for men and women up to age 70, and 800 IUs for older people. Suggested calcium amounts range from 700 mg to 1,300 mg per day, based on age, with an upper limit of 3000 mg. In both cases, intake recommendations cover both food and supplement sources.

So, the authors point out, their findings are specific only to the assigned amounts of vitamin D and calcium taken by women in the study – which are relatively low by today’s standards.

More than 16 million Americans suffer from some form of cognitive impairment, according to the U.S. Centers for Disease Control and Prevention, and the problem is expected to grow as more baby boomers age. Vitamin D might still be viewed as potentially offering a measure of protection against a condition with no formal treatment, if its effects can be decisively demonstrated.

“The sum of information shows conflicting evidence,” said Katherine Tucker of Northeastern University, who was not involved in the current study.

“Some recent studies suggest that too much calcium could have negative effects. The preponderance of evidence shows that vitamin D is protective, but some studies have shown no effect,” she told Reuters Health.

But, Tucker said, “This study by no means closes the door on the need for more research to clarify vitamin D’s effects.”

Rossom’s team acknowledges their study’s limitations. In addition to the doses of supplements in the trial, the results are strictly limited to women, who were mostly white. Also, older age is a significant risk factor for dementia and the study participants, by comparison, were relatively young.

“The next step is to test a higher dose of vitamin D,” said study coauthor JoAnn Manson of Harvard Medical School. “Higher doses will bring a study population to an achieved blood level that has been associated with reduced risk of cognitive decline in (past) studies.”

Manson is currently leading a large clinical trial designed primarily to look at the effects of vitamin D and omega-3′s on cancer risk, but the study will also monitor cognitive function. Results are expected in 2017.

A French study slated to finish next year is examining the cognitive effects of vitamin D versus a placebo in patients who already have Alzheimer’s disease.

“The bottom line is that we still just don’t know,” Tucker told Reuters Health. “We’re in the process of gathering more scientific evidence and will need to continue to do so until more studies point in a certain direction.”

SOURCE: http://bit.ly/VCIs9H Journal of the American Geriatrics Society, online November 23, 2012.

Health News Headlines – Yahoo! News

Read More..

Freeport downgraded as analysts question shift into energy, stock slips

(Reuters) – Shares of Freeport-McMoRan Copper & Gold Inc fell further on Thursday, a day after it said it had struck deals to expand into energy by acquiring Plains Exploration & Production Co and McMoRan Exploration Co for $ 9 billion, and at least four analysts downgraded the miner’s stock.

The transactions, valued at $ 19.6 billion including debt, were lambasted by investors and analysts alike as being unnecessary and a distraction from Freeport‘s copper business.

Freeport shares fell 5 percent to a 15-month low of $ 30.58 in morning trade before recovering slightly. The stock fell 15 percent on Wednesday after the announcement of the deals.

The investor backlash was exacerbated by the disclosure after the announcement that shareholders won’t be allowed to vote on the deal, meaning the only way they have to express their dissatisfaction is to dump the stock.

“We believe that Freeport stock will remain in the penalty box for the foreseeable future and multiples will remain depressed on the back of these acquisition announcements, given investor uncertainty on the strategic merit,” analysts at Goldman Sachs wrote in a research note.

The move into oil and gas means the company will lose its status as a pure-play copper and gold miner, analysts said.

“Freeport’s diversification into oil and gas arguably removes a key investment draw of the company in its copper exposure,” BMO Capital Markets analysts wrote.

Evy Hambro, a managing director at BlackRock, one of Freeport’s top-five shareholders, condemned the deal on Wednesday, saying there was no reason why the three companies should be put together.

Plains shares, which rose 23.4 percent on Wednesday, were down 2.2 percent at $ 43.48 while McMoRan Exploration‘s shares, which had risen 87 percent, were down 3.4 percent at $ 15.27.

The deal’s high debt component was also viewed as negative.

Standard & Poor’s cut its rating outlook on Freeport to negative from stable, including the company’s BBB corporate credit rating. “The negative outlook on Freeport reflects the leveraged nature of the proposed acquisitions, as well as risks associated with integrating the targeted companies,” S&P said.

The cost of protecting debt issued by Freeport against potential default fell slightly after rising sharply on Wednesday immediately after the deal announcement.

Five-year credit default swaps were 1.5 basis points tighter at 153 basis points. That means it costs $ 153,000 a year to protect $ 10 million of debt for five years. The CDS widened about 12 percent on Wednesday.

Yield spreads on the company’s 3.55 percent bonds due March, 2022 widened another 4 basis points to 206 basis points over 10-year Treasuries.

INVESTOR CONCERNS

Freeport said on Wednesday that the rationale for entering into the deal was to use low-cost financing available to the company to make attractive investments.

But analysts including Citigroup’s Brian Yu said there was no or little strategic fit or rationale for the deal.

Yu said he expected the deal to dilute Freeport’s 2013 earnings per share by 3.2 percent.

The Goldman Sachs analysts said Freeport would have to address investor concerns about the valuations of the deal, considering cross-ownership and management links among the three companies.

Both Freeport-McMoRan Copper & Gold and the company now known as McMoRan Exploration Co were spun off in the 1980s and 1990s from the former Freeport-McMoRan Inc.

Jim Bob Moffett is chairman of Freeport-McMoRan and co-chairman and chief executive of McMoRan Exploration. In addition, Plains owns nearly one-third of McMoRan Exploration’s shares after a 2010 asset sale.

Some analysts said the $ 6.9 billion deal for Plains undervalued the company, while $ 2.1 billion for McMoRan was on the high end.

“If the high risk ultra-deep drilling does not work, Freeport greatly overpaid for McMoRan in our view,” analysts at RBC Capital Markets said.

McMoRan has struggled with delays at its Davy Jones deep gas prospect off Louisiana.

Analysts at Nomura said the high debt load made a special dividend less likely and eroded any takeover premium in Freeport’s stock.

Nomura cut its price target on Freeport’s stock to $ 36 from $ 40, while UBS decreased its target $ 40 from $ 47.

Freeport shares were down 3.9 percent at $ 30.91 in early afternoon trading on the New York Stock Exchange.

(Reporting by Swetha Gopinath in Bangalore; Editing by Ted Kerr)

Business News Headlines – Yahoo! News

Read More..